GlassScriptPhysician profile
Deanna A Moore
NPI 1386135515
$5,361.66
in general payments reported to CMS, 2019-2025
26 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $640 · 2023: $2,402 · 2024: $1,905 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,396 · Education: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,395.79 |
| Education | $325.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $866.13 | 2022-2024 | Tremfya |
| Abbvie INC. | $804.33 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $548.01 | 2022-2025 | |
| Genzyme Corporation | $444.95 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $413.48 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $400.80 | 2023-2025 | Zoryve |
| Incyte Corporation | $264.77 | 2022-2025 | Opzelura |
| Ucb, INC. | $202.33 | 2022-2025 | Bimzelx |
| Dermavant Sciences, INC. | $192.87 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $180.38 | 2023-2024 | Ilumya |
| Galderma Laboratories, L.P. | $160.07 | 2023-2024 | Aklief, Oracea, Twyneo |
| Lilly USA, LLC | $152.41 | 2023 | Olumiant, Taltz |
| Leo Pharma INC. | $124.17 | 2022-2023 | Adbry |
| Regeneron Healthcare Solutions, INC. | $91.76 | 2023-2024 | Dupixent, Libtayo |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $83.60 | 2022 | |
| Amgen INC. | $76.41 | 2022-2025 | Otezla, Otezla |
| Pfizer INC. | $51.70 | 2024-2025 | |
| Organon LLC | $46.00 | 2025 | Vtama |
| Revance Therapeutics, INC. | $44.25 | 2024 | Daxxify |
| Biofrontera INC. | $37.40 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.98 | 2022 | |
| Mayne Pharma Commercial LLC | $22.66 | 2023 | |
| Botanix Sb INC | $15.07 | 2025 | Sofdra |
| Journey Medical Corporation | $13.01 | 2023 | |
| Paratek Pharmaceuticals, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.